|
|
Volumn 103, Issue 9, 2011, Pages 708-710
|
|
Inducing indigestion: Companies embrace autophagy inhibitors
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
BECLIN 1;
HYDROXYCHLOROQUINE;
MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR;
PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR;
PHOSPHOTRANSFERASE INHIBITOR;
PLACEBO;
TEMOZOLOMIDE;
TEMSIROLIMUS;
ANTIMALARIAL AGENT;
ANTINEOPLASTIC AGENT;
NEW DRUG;
APOPTOSIS;
AUTOPHAGOSOME;
AUTOPHAGY;
CANCER INHIBITION;
CANCER RESEARCH;
CELL ENERGY;
CELL HYPOXIA;
CELL KILLING;
DRUG INDUSTRY;
DRUG RESEARCH;
ENERGY METABOLISM;
GLIOBLASTOMA;
HUMAN;
KIDNEY CARCINOMA;
LYSOSOME;
MITOCHONDRION;
NONHUMAN;
NOTE;
PANCREAS CANCER;
PRIORITY JOURNAL;
PROTEIN FUNCTION;
SOLID TUMOR;
TUMOR CELL;
TUMOR GROWTH;
TUMOR MICROENVIRONMENT;
TUMOR PROMOTION;
TUMOR SUPPRESSOR GENE;
ANIMAL;
CELL SURVIVAL;
CLINICAL TRIAL (TOPIC);
DISEASE MODEL;
DRUG EFFECT;
METABOLISM;
NEOPLASM;
PATHOLOGY;
PATHOPHYSIOLOGY;
ANIMALS;
ANTIMALARIALS;
ANTINEOPLASTIC AGENTS;
AUTOPHAGY;
CELL HYPOXIA;
CELL SURVIVAL;
CLINICAL TRIALS AS TOPIC;
DISEASE MODELS, ANIMAL;
DRUGS, INVESTIGATIONAL;
HUMANS;
HYDROXYCHLOROQUINE;
NEOPLASMS;
|
|
EID: 79959618195
PISSN: 00278874
EISSN: 14602105
Source Type: Journal
DOI: 10.1093/jnci/djr168 Document Type: Note |
|
Times cited : (24)
|
|
References (0)
|
